MESOBLAST Aktie

 

These shares are having a good session on Tuesday. Let's see why. The post Why DroneShield, IPD, Mesoblast, and Woodside shares are charging higher today appeared first on The Motley Fool Australia....

Shares in Mesoblast edge higher after the company announces a major change to its debt and funding structure. The post This ASX healthcare stock just changed its debt. Here's why it matters appeared first on The Motley Fool Australia....

Mesoblast has option to draw down up to US$125 million by June 30, 2026...

With more than seven million users moving through HotCopper forums every year,…...

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent peer-reviewed comparative analysis of efficacy and safety between remestemcel-L and ruxolitinib for treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) was presented at the 67th ASH Annual meeting in Florida this past week. The independent study authors concluded that remestemcel-L showed superior outcomes in complete and overall remission compared with ruxolitinib.1...

Could FDA approval send this healthcare stock towards further gains? The post How much further upside is there for Mesoblast shares after soaring 23% in a month? appeared first on The Motley Fool Australia....

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at the Piper Sandler 37th Annual Healthcare Conference in New York on December 2–4, 2025....

Two experts have presented their case for buying and selling the ASX biotech stock. The post Mesoblast shares: bull vs. bear appeared first on The Motley Fool Australia....

Sales are growing for this biotech. Let's see what it reported today. The post Mesoblast shares push higher on strong sales update appeared first on The Motley Fool Australia....

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided a trading update, together with a comprehensive operational overview, as part of the Chief Executive's Annual General Meeting (AGM) address....

Analysts have given their verdicts on these shares. The post Should you buy Mesoblast, Paladin Energy, and Xero shares? appeared first on The Motley Fool Australia....

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high rate of non-responsiveness to therapies in adults with severe acute graft versus host disease (aGvHD) who fail corticosteroids, and the high mortality in these patients, Mesoblast and the United States National Institutes of Health (NIH)-funded Blood and Marrow Transplant Clinical Trials Network (BMT CTN) will collaborate on a pivotal trial of Ryoncil® (remestemcel-L-rknd) as part of first-line regimen in adults with severe aGvHD refractory to corticosteroids (SR-aGvHD). The BMT CTN is a body representing U.S. centers responsible for performing approximately 80% of all U.S. allogeneic BMTs....

These shares have been hit with sell ratings. But why? The post Brokers say Mesoblast, NAB, and Pilbara Minerals shares are sells appeared first on The Motley Fool Australia....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company's transition to a fully integrated commercial organization it has appointed James M. O'Brien as its US-based Chief Financial Officer (CFO). Jim has extensive experience in all aspects of financial management and planning having spent the majority of his career with multi-national public and private companies in the life sciences, biotechnology, and pharmaceutical industries....

Find out if the company is set to experience more growth. The post Mesoblast shares surge 60% in a year. Have investors missed the boat? appeared first on The Motley Fool Australia....

After losing some value lately, a hammer chart pattern has been formed for Mesoblast Limited (MESO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term....

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the U.S. Food & Drug Administration (FDA) has scheduled a meeting in early December to discuss Mesoblast's data on opioid reduction and cessation from its first Phase 3 study (MSB-DR003) of rexlemestrocel-L in patients with chronic low back pain (CLBP)....

Mesoblast Limited (MESO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...